A new pharma factory shows how hard it could be for drugmakers to outrun Trump's tariffs
1. Fujifilm's facility will produce drug substances for JNJ and Regeneron. 2. JNJ signed a $2 billion deal to secure production space in North Carolina. 3. The plant is expected to produce 50 million doses annually once fully operational. 4. U.S. manufacturing capabilities for biopharmaceuticals are increasing due to favorable tax policies. 5. Tariffs and COVID-19 concerns are driving companies to enhance U.S. production.